Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Actelion/Celltech Zavesca

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Actelion's type I Gaucher disease therapy Zavesca (miglustat) is approved July 31 as second-line treatment to Genzyme's Cerezyme (imiglucerase) in adults for whom "enzyme replacement therapy is not an option." The firm estimates the eligible population at 200-300 patients. The product will be available to a limited number of physicians due to neuropathy concerns and pregnancy category X status. Actelion and Celltech are studying miglustat in type III Gaucher disease, Niemann-Pick type C and late onset Tay-Sachs..

You may also be interested in...



Indivior Reorganizing And Re-Investing In US Commercial Functions

Indivior aims to cut costs by restructuring its US commercial operations and reducing discretionary spending, in order to improve flexibility in the face of the COVID-19 pandemic and to invest in R&D.

Flying High: Quest Teams With Las Vegas Walmart To Deliver COVID-19 Tests By Drone

Look! Up in the sky! It’s a bird! It’s a plane! It’s … a COVID-19 test from Quest Diagnostics.

Executives On The Move: New CEO Appointed At Xwpharma

New directors at 4D Pharma, Neurogene And Zogenix.

Topics

UsernamePublicRestriction

Register

PS142970

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel